Three Small-Cap Sleepers the Market Forgot — And Why That's About to Change

Forget the megacaps. While Wall Street debates Hormuz disruptions and UK prime ministers, BLMN-style boring sectors are hiding some genuinely weird setups. The Bloomberg FDA peptide story is the one that caught our eye — the FDA is holding a summer meeting to potentially legalize 14 peptides for compounding pharmacies, and the current black market is estimated at $1–2 billion with room to double or triple. That is a textbook regulatory catalyst waiting to happen.

$IMVT (Immunovant, ~$3B market cap) isn't a peptide compounder, but it's a clinical-stage immunology company benefiting from the same tailwind: population-level comfort with self-injection normalized by GLP-1 drugs. Their FcRn inhibitor platform targets autoimmune diseases, and a Phase 3 readout expected later this year is a binary catalyst most retail investors have never heard of. Meanwhile, $TLPH (Talphera — scratch that) — let's talk $PAHC (Phibro Animal Health, ~$800M cap), which quietly services the same compounding-adjacent animal pharma niche and has been building recurring revenue in a sector nobody glamorizes. And for the defense electronics angle, $DRS (Leonardo DRS, ~$7B cap) makes military electronics and sensors — exactly the stuff the Pentagon buys more of every time a Hormuz crisis reminds everyone that hard power still matters.

Three different sectors, three different risk profiles, three companies your group chat has definitely never mentioned. That's kind of the point.